Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Fi
— Corporate priorities for 2022 include initial readout of up to three cabozantinib pivotal trials; initiation of pivotal trial program for XL092; expansion of clinical programs for XL092, XB002 and XL102; and multiple new development candidates from small molecule and biologics programs —— Cabozantinib franchise ac...
Source: pharmiweb.com